Skip to content
DataLookout
Start free
Menu

NCT07239011

Dapagliflozin in Depression

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 20, 2025 to Nov 1, 2025
    • Site details revised
    v2
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

The primary outcome measure was the 17-item HDRS.
Timeframe: 3 months

Secondary (1)

Change in quality of life.

Arms and interventions

Control groupActive comparator

Control group (n =30) who will receive fluoxetine (20 mg) and placebo once daily for 3 months

Dapagliflozin groupActive comparator

Dapagliflozin group (n=30) who will receive fluoxetine (20 mg) once daily plus dapagliflozin 10 mg once daily for 3 months

Drugs: Fluoxetine, Dapagliflozin

Sites

1 site in 1 country

  • Mostafa BahaaDamietta, New Damietta, Egypt